We should be seeing trial result news anytime on Z944 and if positive the drug could enter Phase II trials in the coming weeks. The company stated that it expected this to occur in Q1 in their last earnings report. News could come in the next four weeks. The initiation of Z160 Phase II trials caused a nice 20% pop in Zalicus earlier this year and similar news on Z944 could see the stock move again. Zalicus has also proven that it can attract large pharmaceutical companies to partner with them on drugs so positive news on the Phase I trials could see another deal unfold.